I wasn't able to make it this year...any interesting data? Anything practice-changing? I'm seeing lobster rolls on my academic friends' facebook pages but haven't heard much about new data coming out.
I saw a newsfeed on hypofx for Stage II and III NSCLC. Based on my limited review it's safe and just as effective as standard fx.
who?I did hear a rumor that a particular company (to remain unnamed and unnumbered) was on their way out. Anyone else hear this?
who?
Wouldn't be surprised. I believe they cancelled an ipo a few years ago because they had too much debt, plus there have been several high profile Medicare settlements in the tens of millions in both 21C rad onc and urology in the last couple of yearsThe only company I can think of with both a name and number would be 21st Century
Sounds a lot like when applying to residency. Lots of nerves going through the process, constantly comparing yourself to the stellar applicants out there and wondering how you'd compare, and then it works in the end.Spoke to a few PGY 5 colleagues at a few programs. They went for the ASTRO interviews of course. Both described it as a pretty tight job market. No news there. Both did not have geographic constraints and yet they were very anxious about the whole process. My chief actually told said to me "IF I could do it all over again, I would not have picked this field at all. It's a dead end". He's an intelligent man and yet to hear him say that was disheartening to say the least. I have faith he will find a job but hell if he knows where or under what terms. He said about 30 apps/spot. I have no frame of reference if that's worse,better, or the same as in years past.
I didn't hear that about 21C. For what they did to a patient with metastatic disease who I later saw for whole brain I have a hard time feeling bad for them. What would happen to their facilities